{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:26:38Z","timestamp":1780633598736,"version":"3.54.1"},"reference-count":34,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T00:00:00Z","timestamp":1561334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Economics"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A change in the expectations about future treatments may change the option value of a current treatment, thereby affecting its utilization.<\/jats:p><jats:p>We conducted an interrupted time series analysis using a large administrative claims database to test whether the utilization of existing cancer treatments changed after the disclosures of the then\u2010investigational drug ipilimumab's Phase II and Phase III results among metastatic melanoma patients from 2008 to 2011. We used a multinomial logistic regression to analyze the temporal probability of receiving antineoplastic systemic therapy, surgical resection of metastasis, or both, relative to no treatment, in the first 3\u00a0months following the first metastasis diagnosis.<\/jats:p><jats:p>One thousand eight hundred forty\u2010six metastatic melanoma patients were included. After adjusting for clinical and sociodemographic variables and the underlying time trend, the disclosure of ipilimumab's Phase II result was associated with a nearly twofold immediate increase in the probability of receiving surgical resection of metastasis relative to no treatment, which was significant at 5% level. No significant effect was observed for the time trend. No significant effects were found for the announcement of the Phase III result.<\/jats:p><jats:p>Our findings in metastatic melanoma provide the first empirical evidence of the impact of option value in cancer treatment decision making.<\/jats:p>","DOI":"10.1002\/hec.3899","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T18:26:52Z","timestamp":1561487212000},"page":"855-867","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Do cancer treatments have option value? Real\u2010world evidence from metastatic melanoma"],"prefix":"10.1002","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8537-7872","authenticated-orcid":false,"given":"Meng","family":"Li","sequence":"first","affiliation":[{"name":"Comparative Health Outcomes, Policy and Economics (CHOICE) Institute University of Washington  Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4238-7402","authenticated-orcid":false,"given":"Anirban","family":"Basu","sequence":"additional","affiliation":[{"name":"Comparative Health Outcomes, Policy and Economics (CHOICE) Institute University of Washington  Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline S.","family":"Bennette","sequence":"additional","affiliation":[{"name":"Flatiron Health  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Veenstra","sequence":"additional","affiliation":[{"name":"Comparative Health Outcomes, Policy and Economics (CHOICE) Institute University of Washington  Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis P.","family":"Garrison","sequence":"additional","affiliation":[{"name":"Comparative Health Outcomes, Policy and Economics (CHOICE) Institute University of Washington  Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,6,24]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"American Cancer Society. (2016).Cancer Facts & Figures 2016. Cancer Facts & Figures2016."},{"key":"e_1_2_7_3_1","doi-asserted-by":"crossref","unstructured":"Becker B. Murphy K. &Philipson T.(2007).The value of life near its end and terminal care. NBER working paper. (No. 13333). Cambridge MA.","DOI":"10.3386\/w13333"},{"issue":"6","key":"e_1_2_7_4_1","first-page":"488","article-title":"Treatment of metastatic melanoma: An overview","volume":"23","author":"Bhatia S.","year":"2009","journal-title":"Oncology (Williston Park)"},{"key":"e_1_2_7_5_1","unstructured":"Bristol\u2010Myers Squibb. (2009).Results from Three Phase 2 Studies Reported a Two\u2010Year Survival Rate Ranging from 30 to 42 Percent in Metastatic Melanoma Patients Treated with Ipilimumab (10 mg\/kg)|BMS Newsroom. Retrieved March 26 2017 fromhttp:\/\/bms.newshq.businesswire.com\/press\u2010release\/rd\u2010news\/results\u2010three\u2010phase\u20102\u2010studies\u2010reported\u2010two\u2010year\u2010survival\u2010rate\u2010ranging\u201030\u201042\u2010pe"},{"key":"e_1_2_7_6_1","unstructured":"Bristol\u2010Myers Squibb. (2010).Investigational Compound Ipilimumab Demonstrates Improved Overall Survival in Phase 3 Trial of Previously\u2010Treated Patients with Metastatic Melanoma|BMS Newsroom. Retrieved March 26 2017 fromhttp:\/\/bms.newshq.businesswire.com\/press\u2010release\/rd\u2010news\/investigational\u2010compound\u2010ipilimumab\u2010demonstrates\u2010improved\u2010overall\u2010survival\u2010pha"},{"issue":"2","key":"e_1_2_7_7_1","first-page":"CD001215","article-title":"Systemic treatments for metastatic cutaneous melanoma","author":"Crosby T.","year":"2000","journal-title":"The Cochrane Database of Systematic Reviews"},{"issue":"8","key":"e_1_2_7_8_1","first-page":"980","article-title":"Association of Surgical Treatment, systemic therapy, and survival in patients with abdominal visceral melanoma metastases, 1965\u20102014","volume":"111","author":"Deutsch G.","year":"2017","journal-title":"JAMA Surgery"},{"key":"e_1_2_7_9_1","unstructured":"Frey P.(2013).PDUFA V: Benefit\u2010Risk Assessment and Patient\u2010Focused Drug Development. In FDA REdI conference (pp.1\u201311)."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.12.009"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.2307\/1910997"},{"issue":"24","key":"e_1_2_7_12_1","first-page":"2251","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"362","author":"Hodi S.","year":"2010","journal-title":"The New England Journal of Medicine"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/ecoj.12461"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.12.007"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e31824bc981"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.091074"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.49.2.101"},{"key":"e_1_2_7_18_1","unstructured":"National Cancer Institute. (2015).Drugs approved for melanoma. Retrieved July 8 2016 fromhttp:\/\/www.cancer.gov\/about\u2010cancer\/treatment\/drugs\/melanoma"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1512009"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70938-X"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.3386\/w15649"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-4963-4_9"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.3085"},{"issue":"11","key":"e_1_2_7_24_1","first-page":"265","article-title":"The option value of innovative treatments in the context of chronic myloid leukemia","volume":"18","author":"Sanchez Y.","year":"2012","journal-title":"The American Journal of Managed Care"},{"key":"e_1_2_7_25_1","article-title":"Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma","volume":"1","author":"Sasse A.","year":"2007","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-405X(76)90019-2"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1021904"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1188\/12.ONF.E70-E83"},{"key":"e_1_2_7_29_1","unstructured":"The National Bureau of Economic Research. (2017).ZIP Code Distance Database\u2014ZIP Code Tabulation Area (ZCTA) Distance Database. Retrieved October 1 2017 fromhttp:\/\/www.nber.org\/data\/zip\u2010code\u2010distance\u2010database.html"},{"issue":"10","key":"e_1_2_7_30_1","first-page":"e340","article-title":"The option value of innovative treatments for non\u2010small cell lung cancer and renal cell carcinoma","volume":"23","author":"Thornton Snider J.","year":"2017","journal-title":"The American Journal of Managed Care"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1515\/1558-9544.1306"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1515\/fhep-2016-0014"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.2307\/3665939"},{"key":"e_1_2_7_34_1","unstructured":"U.S. Food and Drug Administration. (2016).Drugs@FDA: FDA Approved Drug Products. Retrieved August 7 2016 fromhttps:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2002.00430.x"}],"container-title":["Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhec.3899","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hec.3899","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hec.3899","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hec.3899","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T17:32:13Z","timestamp":1694367133000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hec.3899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,24]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1002\/hec.3899"],"URL":"https:\/\/doi.org\/10.1002\/hec.3899","archive":["Portico"],"relation":{},"ISSN":["1057-9230","1099-1050"],"issn-type":[{"value":"1057-9230","type":"print"},{"value":"1099-1050","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,24]]},"assertion":[{"value":"2018-05-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}